Zimmer Biomet Holdings, Inc.’s $1.06 Billion Registered Secondary Common Stock Offering

Cravath represented the underwriter, Barclays, in connection with the US$1.06 billion registered secondary common stock offering of Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare. The shares were listed on the New York Stock Exchange. The transaction closed on February 10, 2016.

The Cravath team included partners William J. Whelan III and William V. Fogg and associates Jacob B. Ornstein and Martin P. Pepeljugoski. Alan Campbell also worked on this matter.